Diabeteksen munuaistauti, näytönastekatsausten kirjallisuusviitteet

Kirjallisuutta

1. Adler AI, Stevens RJ, Manley SE, ym. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225-32 «PMID: 12472787»PubMed
2. Agarwal R, Filippatos G, Pitt B, ym. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43(6):474-484 «PMID: 35023547»PubMed
3. Agrawal L, Azad N, Bahn GD, ym. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2018;61(2):295-299 «PMID: 29101421»PubMed
4. Badve SV, Bilal A, Lee MMY, ym. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2025;13(1):15-28 «PMID: 39608381»PubMed
5. Baggio B, Budakovic A, Dalla Vestra M, ym. Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J Am Soc Nephrol 2002;13(11):2730-6 «PMID: 12397043»PubMed
6. Baigent C, Landray MJ, Reith C, ym. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-92 «PMID: 21663949»PubMed
7. Bakris GL, Williams M, Dworkin L, ym. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36(3):646-61 «PMID: 10977801»PubMed
8. Billeter AT, Scheurlen KM, Probst P, ym. Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br J Surg 2018;105(3):168-181 «PMID: 29405276»PubMed
9. Brenner BM, Cooper ME, de Zeeuw D, ym. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9 «PMID: 11565518»PubMed
10. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;(99):S87-93 «PMID: 16336584»PubMed
11. Chase HP, Garg SK, Marshall G, ym. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991;265(5):614-7 «PMID: 1987411»PubMed
12. Chen X, Zhang J, Zhou Z. The effects of metabolic surgery on microvascular complications in obese patients with type 2 diabetes: a meta-analysis. Surg Obes Relat Dis 2021;17(2):434-443 «PMID: 33144039»PubMed
13. Chen Y, Zhi Y, Li C, ym. HDL cholesterol and risk of diabetic nephropathy in patient with type 1 diabetes: A meta-analysis of cohort studies. Diabetes Res Clin Pract 2016;122():84-91 «PMID: 27816683»PubMed
14. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, ym. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81 «PMID: 20483451»PubMed
15. Chuahirun T, Simoni J, Hudson C, ym. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004;327(2):57-67 «PMID: 14770020»PubMed
16. Cohen RV, Pereira TV, Aboud CM, ym. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial. JAMA Surg 2020;155(8):e200420 «PMID: 32492126»PubMed
17. de Boer IH, Gao X, Cleary PA, ym. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 2016;11(11):1969-1977 «PMID: 27797889»PubMed
18. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, ym. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86 «PMID: 8366922»PubMed
19. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157(13):1413-8 «PMID: 9224218»PubMed
20. Dwyer JP, Parving HH, Hunsicker LG, ym. Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med 2012;2(1):1-10 «PMID: 22493597»PubMed
21. . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253-9 «PMID: 10675071»PubMed
22. Einafshar N, Esparham A, Moghani MS, ym. The Impact of Metabolic and Bariatric Surgery on Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. Obes Surg 2025;35(1):329-340 «PMID: 39656373»PubMed
23. Feodoroff M, Harjutsalo V, Forsblom C, ym. Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. Acta Diabetol 2016;53(4):525-33 «PMID: 26668013»PubMed
24. Filippatos G, Anker SD, Agarwal R, ym. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation 2021;143(6):540-552 «PMID: 33198491»PubMed
25. Gaede P, Vedel P, Larsen N, ym. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93 «PMID: 12556541»PubMed
26. Gall MA, Borch-Johnsen K, Hougaard P, ym. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44(11):1303-9 «PMID: 7589828»PubMed
27. Gerstein HC, Mann JF, Yi Q, ym. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286(4):421-6 «PMID: 11466120»PubMed
28. Gozzoli V, Palmer AJ, Brandt A ym. [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients]. Dtsch Med Wochenschr 2000;125:1154-9
29. Groop PH, Thomas MC, Moran JL, ym. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58(7):1651-8 «PMID: 19401416»PubMed
30. Heerspink HJL, Stefánsson BV, Correa-Rotter R, ym. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383(15):1436-1446 «PMID: 32970396»PubMed
31. Holman RR, Paul SK, Bethel MA, ym. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89 «PMID: 18784090»PubMed
32. . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53 «PMID: 9742976»PubMed
33. Jansson FJ, Forsblom C, Harjutsalo V, ym. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study. Diabetologia 2018;61(5):1203-1211 «PMID: 29423580»PubMed
34. Koye DN, Magliano DJ, Reid CM, ym. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2018;72(5):653-661 «PMID: 29784612»PubMed
35. Kramer HJ, Nguyen QD, Curhan G, ym. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289(24):3273-7 «PMID: 12824208»PubMed
36. Lewis EJ, Hunsicker LG, Bain RP, ym. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62 «PMID: 8413456»PubMed
37. Lewis EJ, Hunsicker LG, Clarke WR, ym. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60 «PMID: 11565517»PubMed
38. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995;38(5):610-6 «PMID: 7489846»PubMed
39. Metsärinne K, Bröijersen A, Kantola I, ym. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Prim Care Diabetes 2015;9(1):31-8 «PMID: 25066820»PubMed
40. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310(6):356-60 «PMID: 6690964»PubMed
41. Nathan DM, Cleary PA, Backlund JY, ym. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643-53 «PMID: 16371630»PubMed
42. Newman DJ, Mattock MB, Dawnay AB, ym. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005;9(30):iii-vi, xiii-163 «PMID: 16095545»PubMed
43. Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400(10365):1788-1801 «PMID: 36351458»PubMed
44. O'Brien R, Johnson E, Haneuse S, ym. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med 2018;169(5):300-310 «PMID: 30083761»PubMed
45. Oellgaard J, Gæde P, Rossing P, ym. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61(8):1724-1733 «PMID: 29850922»PubMed
46. Packham DK, Alves TP, Dwyer JP, ym. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012;59(1):75-83 «PMID: 22051245»PubMed
47. Palmer SC, Navaneethan SD, Craig JC, ym. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014;(5):CD007784 «PMID: 24880031»PubMed
48. Parving HH, Lehnert H, Bröchner-Mortensen J, ym. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8 «PMID: 11565519»PubMed
49. Penno G, Solini A, Bonora E, ym. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011;29(9):1802-9 «PMID: 21738053»PubMed
50. Penno G, Solini A, Bonora E, ym. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetol 2018;55(6):603-612 «PMID: 29574497»PubMed
51. Penno G, Solini A, Orsi E, ym. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia 2018;61(11):2277-2289 «PMID: 30032426»PubMed
52. Perkins BA, Ficociello LH, Roshan B, ym. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77(1):57-64 «PMID: 19847154»PubMed
53. Perkovic V, Jardine MJ, Neal B, ym. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;380(24):2295-2306 «PMID: 30990260»PubMed
54. Perkovic V, Tuttle KR, Rossing P, ym. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391(2):109-121 «PMID: 38785209»PubMed
55. Persson F, Lindhardt M, Rossing P, ym. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. J Renin Angiotensin Aldosterone Syst 2016;17(3): «PMID: 27488274»PubMed
56. Pitt B, Filippatos G, Agarwal R, ym. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385(24):2252-2263 «PMID: 34449181»PubMed
57. Rahman M, Baimbridge C, Davis BR, ym. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008;52(3):412-24 «PMID: 18676075»PubMed
58. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9
59. Retnakaran R, Cull CA, Thorne KI, ym. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55(6):1832-9 «PMID: 16731850»PubMed
60. Rodríguez-Gutiérrez R, Montori VM. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes 2016;9(5):504-12 «PMID: 27553599»PubMed
61. Ruggenenti P, Fassi A, Ilieva AP, ym. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351(19):1941-51 «PMID: 15516697»PubMed
62. Ruggenenti P, Porrini E, Motterlini N, ym. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 2012;23(10):1717-24 «PMID: 22935482»PubMed
63. Ruospo M, Saglimbene VM, Palmer SC, ym. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017;6(6):CD010137 «PMID: 28594069»PubMed
64. Sawicki PT, Didjurgeit U, Mühlhauser I, ym. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17(2):126-31 «PMID: 8137682»PubMed
65. Sun S, Hisland L, Grenet G, ym. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials. Therapie 2022;77(4):413-423 «PMID: 34782145»PubMed
66. Targher G, Zoppini G, Chonchol M, ym. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 2011;21(4):294-301 «PMID: 20096544»PubMed
67. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
68. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, ym. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023;388(2):117-127
69. Thomas MC, Macisaac RJ, Jerums G, ym. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009;32(8):1497-502 «PMID: 19470839»PubMed
70. Thorn LM, Gordin D, Harjutsalo V, ym. The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes. Diabetes Care 2015;38(11):2128-33 «PMID: 26310691»PubMed
71. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13
72. Writing Group for the CKD Prognosis Consortium, Grams ME, Coresh J, ym. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA 2023;330(13):1266-1277 «PMID: 37787795»PubMed
73. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290(16):2159-67 «PMID: 14570951»PubMed
74. Zhou JJ, Koska J, Bahn G, ym. Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT. J Clin Endocrinol Metab 2021;106(4):1150-1162 «PMID: 33367811»PubMed
75. Zhu HG, Jiang ZS, Gong PY, ym. Efficacy of low-protein diet for diabetic nephropathy: a systematic review of randomized controlled trials. Lipids Health Dis 2018;17(1):141 «PMID: 29914534»PubMed
76. Zoungas S, Arima H, Gerstein HC, ym. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5(6):431-437 «PMID: 28365411»PubMed